Navigation Links
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Date:10/29/2008

Co-founder of and Former Senior Executive at ImClone Brings Substantial Oncology Drug Development Expertise

NEW BRUNSWICK, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today the appointment of Harlan W. Waksal, M.D., 55 to its board of directors. Senesco's board of directors now consists of nine members, seven of whom are independent.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 )

Dr. Waksal is the President and Sole Proprietor of Waksal Consulting L.L.C., which was founded in 2003 and provides strategic business and clinical development counsel to biotechnology companies. Dr. Waksal co-founded the biotechnology company, ImClone Systems Incorporated, in 1984. He served at ImClone in a variety of senior roles over a 16 year period, beginning in 1987. During his tenures as Chief Operating Officer, from 1987 through 2002, and Chief Executive Officer, from 2002 until 2003, Dr. Waksal was instrumental in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells, called the epidermal growth factor receptor (EGFR).

"Senesco is very pleased to have Dr. Waksal join our Board," said Rudolf Stalder, Chairman of Senesco's Board. "His significant contribution to the clinical development of Erbitux, and vast knowledge of the oncology space, will provide critical industry insight to Senesco."

"We look forward to working with Dr. Waksal as we move toward our goal of filing an IND for multiple myeloma," said Bruce Galton, President & Chief Executive Officer of Senesco. "We believe his extensive and distinguished work in the biotechnology industry will be a great resource in our oncology drug development efforts."

Dr. Waksal is the author of 50 published scientific papers, many in the area of oncology. He currently serves on a number of non-corporate boards, including the American Committee for the Weizmann Institute of Science in New York, NY, Oberlin College in Oberlin, OH and the Montclair Art Museum in Montclair, NJ. Dr. Waksal also serves on the Technology Advisory Board for the New Jersey Edison Innovation Fund.

He earned his B.A. in biology from Oberlin College in 1975, and received his M.D. from Tufts University School of Medicine, Boston, MA.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BOSTON , Feb. 10, 2016  Matchbook, ... sourcing for fast growing biotech companies, announced today ... Senior Procurement Strategic Advisor. Jim brings nearly 25 ... sourcing and procurement, having spent nearly two decades ... Supply Chain/Logistics and Procurement at Genzyme and, most ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor ... expecting to fill more than 100 tables for its annual event, which will ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports ... program, Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over ... Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today that the ... provides capabilities for managing and processing genomic and health data at petabyte scale. ... collecting and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. ...
Breaking Biology Technology:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
Breaking Biology News(10 mins):